Leveraging Population-Based Clinical Quantitative Phenotyping for Drug Repositioning.

Area of Science:

• Pharmacology
• Computational Biology
• Clinical Research

Background:

• Computational drug repositioning offers a scalable approach to identify new therapeutic uses for existing drugs, potentially reducing development risks.
• Current methods often overlook individual-level phenotypic data, limiting the potential for biomarker-driven drug discovery.
• Integrating routine clinical phenotypes with drug usage data presents an opportunity for novel repositioning strategies.

Purpose of the Study:

• To propose and validate a framework for discovering drug-phenotype associations in cross-sectional observational studies.
• To identify potential drug repositioning hypotheses by analyzing routine clinical data in a healthy population.
• To assess the utility of cross-sectional studies for uncovering serendipitous drug interactions.

Main Methods:

• Utilized a healthy, nondiabetic population from the National Health and Nutrition Examination Survey (NHANES) to minimize confounding by indication.
• Combined complementary diagnostic phenotypes (fasting glucose and glucose response) with prescription drug usage data.
• Confirmed phenotype-drug associations using retrospective self-controlled case analysis on de-identified insurance claims data (Aetna).

Main Results:

• The framework successfully identified potential associations between routine clinical phenotypes and drug usage in a healthy cohort.
• Bupropion was identified as a plausible glucose-lowering agent.
• The findings suggest that cross-sectional studies of healthy populations can generate valuable drug repositioning hypotheses.

Conclusions:

• A novel framework enables the discovery of drug repositioning hypotheses from cross-sectional observational studies of routine clinical data.
• Bupropion's potential glucose-lowering effect warrants further investigation for clinical application.
• This approach demonstrates the feasibility of leveraging data from healthy individuals for identifying new therapeutic uses of existing drugs.